| Identification | Back Directory | [Name]
Zicronapine | [CAS]
170381-16-5 | [Synonyms]
Lu31130
Lu-31130
Lu31-130
Lu 31130
Lu 31-130
Lu-31-130
Zicronapine
Piperazine, 4-[(1R,3S)-6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl]-1,2,2-trimethyl- | [Molecular Formula]
C22H27ClN2 | [MDL Number]
MFCD19443717 | [MOL File]
170381-16-5.mol | [Molecular Weight]
354.92 |
| Hazard Information | Back Directory | [Uses]
Zicronapine is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors. | [Definition]
ChEBI: Zicronapine is a member of indanes. | [References]
[1] Lopez De Diego, Heidi. et al. Succinate and malonate salts of trans-4-(1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and their preparation, pharmaceutical compositions, and use as medicaments, particularly as antipsychotics. WO2005016900A1
[2] Lundbeck H. A/S. The clinical phase III programme commenced on zicronapine. 20 Jan 2011.
[3] Lundbeck H, A/S. Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia –planning for continued clinical work. Press release No. 392 18 December 2009. |
|
|